A Study to Evaluate RO7566802
Phase 1
250
about 4.1 years
18+
6 sites in AL, CT, NY +3
What this study is about
Researchers are testing the safety, how it works in the body (pharmacokinetics), and if it helps fight cancer (activity) of a new drug called RO7566802. The trial will be given alone or with atezolizumab to people with locally advanced, recurrent, or metastatic solid tumors.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Atezolizumab
- 2.Take RO7566802
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
atezolizumab
injection (Injection)
Primary: Number of Participants with Dose-limiting Toxicity (DLTs), Percentage of Participants with Adverse Events (AEs) Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)
Secondary: Area Under the Serum Concentration Time Curve (AUC) of RO7566802, Maximum Serum Concentration (Cmax) of RO7566802, Objective Response Rate as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), Total Clearance (CL) of RO7566802
Oncology